Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT04067336 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT04067336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04067336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 12, 2019
Completion date
October 16, 2028
Enrollment
263 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute myeloid leukemia, advanced malignant neoplasm, mixed lineage acute leukemia, mixed lineage leukemia, mixed phenotype acute leukemia